Wei Wei

Has grant

Assistant Professor

Yale University School of Medicine

United States

Research Interests

Explore related searches

Professors in United States Professors in Immunology Immunology professors in United States

Contact this professor

Get a free first email built on one of their papers, ready for you to edit and send yourself.

About

Wei Wei is an Assistant Professor at the Yale School of Medicine in the United States. His research focuses on statistical methodologies in clinical trials, particularly in the context of cancer treatment and immunotherapy, as evidenced by his recent articles. He has contributed to studies discussing the Maximum Negative Hypergeometric Distribution, treatment effects under non-proportional hazard scenarios, and the implications of immune checkpoint inhibitors on cardiovascular health.

Recent Grants

Grant: Close

Yale Head and Neck Cancer SPORE: Overcoming Treatment Resistance in Head and Neck Cancer

Open Date: 2020-09-22

Close Date: 2025-06-30

Grant: Close

VICKtOrY Early Clinical Trials Consortium

Open Date: 2014-07-10

Close Date: 2026-02-28

Articles (10)

Year:

2025

Year:

2025

Year:

2024

Year:

2024

Year:

2024

Year:

2024

Year:

2024

Year:

2024

Year:

2024

Year:

2024

Collaborators (3)

Benjamin Lu

Yale University

UNITED STATES

View details

Lakshmanan Krishnamurti

UNITED STATES

View details

Daniel Zelterman

Professor

Yale School of Public Health

UNITED STATES

View details

ApplyKite TwinLearns as you apply

Make your next move.

Prepare your application

Review drafts before you send them.

Wei Wei

Research Interests

Explore related searches

Contact this professor

About

Recent Grants

Articles (10)

The Maximum Negative Hypergeometric Distribution

Statistical considerations for evaluating treatment effect under various non-proportional hazard scenarios

Adverse cardiovascular events and cardiac imaging findings in patients on immune checkpoint inhibitors

Circulating tumor-reactive KIR+CD8+ T cells suppress anti-tumor immunity in patients with melanoma

Propensity score weighted multi‐source exchangeability models for incorporating external control data in randomized clinical trials

Machine-Learning Predictive Tool for the Individualized Prediction of Outcomes of Hematopoietic Cell Transplantation for Sickle Cell Disease: A Registry Based Study (Preprint)

A Bayesian platform trial design with hybrid control based on multisource exchangeability modelling

rBMA: A robust Bayesian Model Averaging Method for phase II basket trials based on informative mixture priors

A Phase II Trial of the CD40 Agonistic Antibody Sotigalimab (APX005M) in Combination with Nivolumab in Subjects with Metastatic Melanoma with Confirmed Disease Progression on Anti-PD-1 Therapy

A multicenter phase Ib trial of the histone deacetylase inhibitor entinostat in combination with pembrolizumab in patients with myelodysplastic syndromes/neoplasms or acute myeloid leukemia refractory to hypomethylating agents

Collaborators (3)

Benjamin Lu

Lakshmanan Krishnamurti

Daniel Zelterman

Make your next move.